Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
MRUS Stock Chart & Stats
$94.88
-$0.87(-2.01%)
At close: 4:00 PM EST
$94.88
-$0.87(-2.01%)
Day’s Range― - ―
52-Week Range$33.19 - $95.04
Previous CloseN/A
Volume56.75K
Average Volume (3M)3.69M
Market Cap
$7.15B
Enterprise Value$3.04B
Total Cash (Recent Filing)$710.22M
Total Debt (Recent Filing)$11.00M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Oct 30, 2025EPS Estimate
-1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding75,784,440
10 Day Avg. Volume2,360,113
30 Day Avg. Volume3,690,313
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue54.07
Enterprise Value/Gross Profit54.07
Enterprise Value/Ebitda-7.84
Forecast
1Y Price Target
$97.71Price Target Upside2.98% Upside
Rating ConsensusHold
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPetosemtamab is showing strong signals of clinical activity, which warrants further evaluation in these settings.
Market PotentialAnalyst's market perform rating on MRUS is based on the expectation that the Genmab-Merus transaction will close on time, realizing a significant share value.
Treatment EfficacyThe combination of petosemtamab with FOLFOX/FOLRIRI showed a 100% Overall Response Rate in the 1L setting, outperforming historical trials.
Bears Say
Data InterpretationEfficacy data from petosemtamab is difficult to interpret across treatment lines, especially in the 2L/3L segments.
Data MaturityThe dataset is small, and too immature to provide insight into durability.
Efficacy ConcernsIn the 3L+ setting, only 1 out of 14 patients responded to petosemtamab monotherapy, indicating limited efficacy in this difficult-to-treat population.
Merus News
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $33.19 and its highest was $95.04 in the past 12 months.
What is Merus NV’s market cap?
Merus NV’s market cap is $7.15B.
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Oct 30, 2025 which is in 4 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Aug 05, 2025. The company reported -$2.23 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$1.065.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -1.37.
How many shares outstanding does Merus NV have?
Merus NV has 75,784,440 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$2.23 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went down -2.832%.
Which hedge fund is a major shareholder of Merus NV?
Currently, no hedge funds are holding shares in MRUS
Merus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$97.71 (2.98% Upside)
$97.71 (2.98% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 742.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.41%
12-Months-Change
Fundamentals
Return on Equity
-48.54%
Trailing 12-Months
Asset Growth
9.86%
Trailing 12-Months
Company Description
Merus NV
Merus (MRUS) is a clinical-stage biopharmaceutical company focused on the development of innovative antibody therapeutics for the treatment of cancer. The company is primarily engaged in the discovery and development of bispecific antibodies, which are designed to engage multiple targets in the tumor microenvironment, thereby enhancing the therapeutic efficacy against various cancer types. Merus operates within the biotechnology sector and aims to bring its proprietary antibody-based treatments to market through rigorous clinical trials and collaborations with other pharmaceutical companies.
MRUS Stock 12 Month Forecast
Average Price Target
$97.71
▲(2.98% Upside)
Technical Analysis
PTC Therapeutics
―
Zai Lab
―
Krystal Biotech
―
Akero Therapeutics
―
Avidity Biosciences
―
Ownership Overview
0.15% Insiders
21.42% Mutual Funds
0.09% Other Institutional Investors
76.08% Public Companies and
Individual Investors